NFL Biosciences SA (ALNFL) Stock Statistics & Valuation Metrics
Total Valuation
NFL Biosciences SA has a market cap or net worth of EUR 5.68M. The enterprise value is EUR 11.98M.
- Market Cap
- EUR 5.68M
- Enterprise Value
- EUR 11.98M
Share Statistics
NFL Biosciences SA has 12,672,242 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 12,672,242
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
NFL Biosciences SA’s return on equity (ROE) is -10.84 and return on invested capital (ROIC) is -374.78%.
- Return on Equity (ROE)
- -10.84
- Return on Assets (ROA)
- -0.91
- Return on Invested Capital (ROIC)
- -374.78%
- Return on Capital Employed (ROCE)
- -5.23
- Revenue Per Employee
- 0
- Profits Per Employee
- -829.49K
- Employee Count
- 4
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of NFL Biosciences SA is -1.88. NFL Biosciences SA’s PEG ratio is -0.12.
- PE Ratio
- -1.88
- PS Ratio
- 0.00
- PB Ratio
- -6.16
- Price to FCF
- 0.00
- Price to Operating Cash Flow
- 0.00
- PEG Ratio
- -0.12
Income Statement
In the last 12 months, NFL Biosciences SA had revenue of 0 and earned -3.32M in profits. Earnings per share was -0.26.
- Revenue
- 0
- Gross Profit
- -2.52M
- Operating Income
- -3.87M
- Pretax Income
- -3.86M
- Net Income
- -3.32M
- EBITDA
- -3.76M
- Earnings Per Share (EPS)
- -0.26
Cash Flow
In the last 12 months, operating cash flow was 0 and capital expenditures 0, giving a free cash flow of 0 billion.
- Operating Cash Flow
- 0
- Free Cash Flow
- 0
- Free Cash Flow per Share
- 0.00
Dividends & Yields
NFL Biosciences SA pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.00%
- Earnings Yield
- -53.34%
Stock Price Statistics
- Beta
- 1.06
- 52-Week Price Change
- -60.87%
- 50-Day Moving Average
- 0.72
- 200-Day Moving Average
- 0.93
- Relative Strength Index (RSI)
- 26.82
- Average Volume (3m)
- 36.70K
Important Dates
NFL Biosciences SA upcoming earnings date is Mar 29, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 22, 2026
- Next Earnings Date
- Mar 29, 2027
- Ex-Dividend Date
- ―
Financial Position
NFL Biosciences SA as a current ratio of 1.17, with Debt / Equity ratio of 190.30%
- Current Ratio
- 1.17
- Quick Ratio
- 1.17
- Debt to Market Cap
- 0.04
- Net Debt to EBITDA
- 0.38
- Interest Coverage Ratio
- -272.89
Taxes
In the past 12 months, NFL Biosciences SA has paid -539.78K in taxes.
- Income Tax
- -539.78K
- Effective Tax Rate
- 0.14
Enterprise Valuation
NFL Biosciences SA EV to EBITDA ratio is -1.61, with an EV/FCF ratio of 0.00.
- EV to Sales
- 0.00
- EV to EBITDA
- -1.61
- EV to Free Cash Flow
- 0.00
- EV to Operating Cash Flow
- 0.00
Balance Sheet
NFL Biosciences SA has EUR 2.20M in cash and marketable securities with EUR 582.59K in debt, giving a net cash position of EUR 1.62M billion.
- Cash & Marketable Securities
- EUR 2.20M
- Total Debt
- EUR 582.59K
- Net Cash
- EUR 1.62M
- Net Cash Per Share
- EUR 0.13
- Tangible Book Value Per Share
- EUR 0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for NFL Biosciences SA is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 15.56%